DoximityNYSE: DOCS

Doximity (DOCS) closed at $41.88 in the latest trading session, marking a +1.11% move from the prior day.

In the most recent trading session, Doximity (DOCS) closed at $41.42, indicating a -1.76% shift from the previous trading day.

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most.

Doximity (DOCS) is trading near its 52-week high after getting an upgrade from Barclays. George Tsilis talks about why the "LinkedIn for physicians" can be gaining investor interest.

Doximity (DOCS) reachead $40.88 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.

Doximity recently reported strong financial results. The company has solid growth opportunities.

Doximity's guidance in no way reflects the positive tea leaves management discussed during the conference call. Doximity reported better than expected Q1 results with revenues of $127 million and adjusted EBITDA of $66 million, leading to a 39% increase in share price. The company minimally increased its adjusted EBITDA forecast for FY '25, but potential for sustainable growth rates is not reflected in consensus estimates.

Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research.

Doximity reported strong Q1 FY25 earnings with revenue and Adjusted EBITDA growing 17% and 41% YoY respectively, beating estimates. It saw a 16% increase in customer count in its $500K+ Subscription revenue cohort, while usage of its products continued to grow steadily, alongside expanding margins. Although the management sounded cautious on the state of the economy, it believes that its product innovation should help it capture larger pharma budgets in the coming years.